Abstract
The need of early, preclinical detection of disease is given by the fact that in 50% of patients dying due to coronary death, mortality is neither heralded by cardiac symptoms nor diagnosis make .The risk during life of suffering of consequences of atherosclerosis can be efficiently assessed through the Framingham risk score (among several other global risk scores). Global risk scores although originally formulated to give a numerical estimate of the risk, give generally a rough categorization of the patient into a low, (0-10%) intermediate (10%-20%) or high (>20%) risk. Furthermore the boarders between intermediate and low or high risk are frequently not uniform. Although global risk score evaluation are considered efficient tools in medical practice, over- or underestimation of risk has been reported in several studies. These are the mean reason why many investigators embarked during the last two decades in an effort to discover newer predictive markers. Among them few have passed the threshold of a rigorous assessment of their predictive power including analysis not only of statistical association but also of calibration, discrimination, and reclassification.
Keywords: Biomarkers, atherosclerosis, CRP, vascular imaging, predictors, risk factors
Current Vascular Pharmacology
Title:The Utility of Emerging Biomarkers and Imaging for Assessment of Cardiovascular Risk
Volume: 10 Issue: 6
Author(s): Augusto Gallino
Affiliation:
Keywords: Biomarkers, atherosclerosis, CRP, vascular imaging, predictors, risk factors
Abstract: The need of early, preclinical detection of disease is given by the fact that in 50% of patients dying due to coronary death, mortality is neither heralded by cardiac symptoms nor diagnosis make .The risk during life of suffering of consequences of atherosclerosis can be efficiently assessed through the Framingham risk score (among several other global risk scores). Global risk scores although originally formulated to give a numerical estimate of the risk, give generally a rough categorization of the patient into a low, (0-10%) intermediate (10%-20%) or high (>20%) risk. Furthermore the boarders between intermediate and low or high risk are frequently not uniform. Although global risk score evaluation are considered efficient tools in medical practice, over- or underestimation of risk has been reported in several studies. These are the mean reason why many investigators embarked during the last two decades in an effort to discover newer predictive markers. Among them few have passed the threshold of a rigorous assessment of their predictive power including analysis not only of statistical association but also of calibration, discrimination, and reclassification.
Export Options
About this article
Cite this article as:
Gallino Augusto, The Utility of Emerging Biomarkers and Imaging for Assessment of Cardiovascular Risk, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520873
DOI https://dx.doi.org/10.2174/157016112803520873 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanodiagnostic Attainments and Clinical Perspectives on C-Reactive Protein: Cardiovascular Disease Risks Assessment
Current Medicinal Chemistry New Class of Pyrimidinesulfamoyl Containing Pyrazole and Pyrrole Derivatives and Their Antioxidant Activity
Letters in Organic Chemistry microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Recent Advances and Patents on Mechanical Circulatory Support Devices
Recent Patents on Biomedical Engineering (Discontinued) Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Current Medicinal Chemistry Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued)